Bora Pharmaceuticals
保瑞藥業股份有限公司
Bora Pharmaceuticals is a Taiwan TWSE-listed biotechnology company; its most advanced asset is Cyclosporine Ophthalmic Emulsion (FDA generic drug approval, Dry eye disease), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| Cyclosporine Ophthalmic Emulsion | — | FDA generic drug approval | Dry eye disease | United States | 2026-01-22 | Company disclosure |
| Deflazacort Tablet | — | FDA generic approval | Duchenne muscular dystrophy | United States | 2024-11-06 | Company disclosure |
| Dexlansoprazole DR Capsules | — | Marketing authorization obtained | Gastroesophageal reflux disease | United States | — | Company disclosure |
Key events
- Cyclosporine ophthalmic emulsion generic approved by FDA, as reported by a subsidiary (company disclosure)
- U.S. subsidiary KYMBEE branded-generic launch announced (company disclosure)